Webinar

BUILDING ACCESS INTO PHARMACEUTICAL R&D AGREEMENTS: IDEAS AND POSSIBILITIES FROM REAL-WORLD CONTRACTS

Julia Barnes-Weise, Viviana Galli

28 October 2020

Q&A Session with the Participants

16:03:40
From Global Health Centre Research, Graduate Institute Geneva : Dear all, welcome to our webinar series. Please remember that the session is being recorded and recordings and materials from all webinars are available at the Knowledge Network for Innovation and Access to Medicines at www.knowledgeportalia.org

16:04:23
From Global Health Centre Research, Graduate Institute Geneva : Please type any comments or questions here in the chat, or use the raise hand function if you wish to pose a question orally.

16:04:47
From Global Health Centre Research, Graduate Institute Geneva : Do not forget to select send to “panelists and attendees”

16:26:15
From Judit Rius Sanjuan : Thank you for presenting on this important tool. As the guide was conceptualized during Ebola given difficulties accessing terms and concluding R&D/Access negotiations, I would be interested in hearing your thoughts on how this has improved (or not) during COVID-19.

16:26:21
From Donna Meyer : Does guide address how to factor public funding into pricing and access agreements?

16:27:08
From David Patterson : The Development Stage menu does not contain the rollout stage - e.g. of vaccines? Is this intended to be covered? perhaps there is another term which covers it?

16:29:03
From Elizabeth Gardiner : how can the access provisions be flexible enough to adapt to changing circumstances during the long development period? what have you learned on this topic?

16:40:03
From Norbert Wilk : How much of the contents of agreements are actually available? I am concerned that a large (maybe crucial) part of agreements may be kept commercial in confidence. Is it the case here? Do you attempt to push the transparency bar higher and make more content of the agreements publicly available?

16:40:41
From Laura Hoemeke : How can the MAPGuide be optimized to facilitate COVID19-related agreements?

16:44:04
From Roz Scourse : If conditions are attached to contracts with companies that have multiple global funders (e.g. a global COVID-19 vaccine developer such as AstraZeneca), how can one government ensure that condition is implemented if others do not require it (or even if others have an opposing requirement)?

16:50:15
From Adrián Alonso Ruiz : One example of access conditions linked to public funding was CEPI's Access Policy, that was reviewed in 2018 as some potential recipients saw these conditions too rigid. Is the current R&D business model (e.g. overly reliant on maximising shareholder value) fit for the implementation of access clauses?

16:53:00
From Brook Baker : Moderna is not yet agreeing to license/transfer all the biologic resources and complex manufacturing know-how needed for someone to actually manufacture their vaccine.

16:53:14
From Mohga Kamal-Yanni : Different liability stop Moderna... to export?

16:53:49
From Mohga Kamal-Yanni : is it fair to put liability on poor countries? if not who should carry it?

16:54:42
From Mohga Kamal-Yanni : Q: public conditions including price/affordability in EU/US and in LMICs.

17:05:27
From Paloma Fernández : congratulations for the initiative and excellent session.

17:05:31
From silvana leite : Thanks for the opportunity. Excellent session.

17:05:36
From Norbert Wilk : Thank you for the webinar. Just a leaving comment: From JB-W comments it turns out that the main reason for lack of transparency (other than CIC) is not to turn circumstantial exceptions into widely acceptable practice. What if such an exceptional clause was associated with some description of the circumstances (both in the agreement and later in its disclosed form)? If it is not the case, lack of transparency may look as if someone had a concern that some public interest was traded too cheap with a private company. We have to keep in mind that we are talking about large PUBLIC money involvement.

17:05:37
From Global Health Centre Research, Graduate Institute Geneva : Thank you everyone for attending the webinar. Recording and materials will be available soon at the Knowledge Portal for Innovation and Access to Medicines - www.knowledgeportalia.org